---
document_datetime: 2025-12-29 11:55:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/renvela.html
document_name: renvela.html
version: success
processing_time: 0.1320755
conversion_datetime: 2025-12-30 10:05:44.940705
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Renvela

[RSS](/en/individual-human-medicine.xml/66128)

##### Authorised

This medicine is authorised for use in the European Union

sevelamer carbonate Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Renvela](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Renvela is a medicine used to control hyperphosphataemia (high blood phosphate levels) in:

- adult patients on dialysis (a technique to remove unwanted substances from the blood);
- adults and children from 6 years of age with chronic (long term) kidney disease.

Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease. It contains the active substance sevelamer carbonate.

Expand section

Collapse section

## How is Renvela used?

Renvela is available as tablets (800 mg) and as powder (0.8 g, 1.6 g and 2.4 g) in a sachet to be taken 3 times a day with meals. The dose to take depends on the patient's level of blood phosphate and, in case of children, their height and weight. Renvela must not be taken on an empty stomach and patients should keep to their prescribed diets. The medicine can only be obtained with a prescription. For more information about using Renvela, see the package leaflet or contact your doctor or pharmacist.

## How does Renvela work?

The active substance in Renvela, sevelamer carbonate, is a phosphate binder. When taken with meals, it attaches in the gut to phosphate from food, thereby preventing the phosphate from being absorbed into the body and helping reduce phosphate levels in the blood.

## What benefits of Renvela have been shown in studies?

Renvela has been shown in studies to be effective at lowering levels of blood phosphate in patients with hyperphosphataemia.

In two main studies in 110 adults with kidney disease who were on dialysis, Renvela brought phosphate levels down to around 1.5-1.6 mmol/l (which is within or close to the normal range) and was as effective as another authorised medicine Renagel.

In a third main study in 49 adults who were not on dialysis, Renvela reduced phosphate levels from 2.0 mmol/l to 1.6 mmol/l.

Finally, a main study also showed that Renvela was effective at lowering phosphate levels in 100 children: children who took Renvela had a greater reduction in phosphorous (0.87 mg/dl) than those taking placebo (a dummy treatment) who had a rise in phosphorous of 0.04 mg/dl.

## What are the risks associated with Renvela?

The most common side effects with Renvela (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting, upper abdominal (belly) pain and constipation. For the full list of side effects with Renvela, see the package leaflet.

Renvela must not be used in people with low blood phosphate levels or with bowel obstruction (a blockage in the gut). For the full list of restrictions, see the package leaflet.

## Why is Renvela authorised in the EU?

Studies show that Renvela is effective at reducing levels of blood phosphate in patients with hyperphosphataemia, and its side effects are considered manageable. The European Medicines Agency therefore concluded that Renvela's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Renvela?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Renvela have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Renvela are continuously monitored. Side effects reported with Renvela are carefully evaluated and any necessary action taken to protect patients.

## Other information about Renvela

Renvela received a marketing authorisation valid throughout the EU on 10 June 2009.

Renvela : EPAR - Medicine overview

Reference Number: EMA/357790/2019

English (EN) (83.39 KB - PDF)

**First published:** 23/06/2009

**Last updated:** 19/07/2019

[View](/en/documents/overview/renvela-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-649)

български (BG) (109.26 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/bg/documents/overview/renvela-epar-medicine-overview_bg.pdf)

español (ES) (82.57 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/es/documents/overview/renvela-epar-medicine-overview_es.pdf)

čeština (CS) (104.95 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/cs/documents/overview/renvela-epar-medicine-overview_cs.pdf)

dansk (DA) (81.78 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/da/documents/overview/renvela-epar-medicine-overview_da.pdf)

Deutsch (DE) (84.13 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/de/documents/overview/renvela-epar-medicine-overview_de.pdf)

eesti keel (ET) (81.53 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/et/documents/overview/renvela-epar-medicine-overview_et.pdf)

ελληνικά (EL) (115.96 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/el/documents/overview/renvela-epar-medicine-overview_el.pdf)

français (FR) (84.52 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/fr/documents/overview/renvela-epar-medicine-overview_fr.pdf)

hrvatski (HR) (100.37 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/hr/documents/overview/renvela-epar-medicine-overview_hr.pdf)

italiano (IT) (82.03 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/it/documents/overview/renvela-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (110.83 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/lv/documents/overview/renvela-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (104.56 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/lt/documents/overview/renvela-epar-medicine-overview_lt.pdf)

magyar (HU) (101.08 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/hu/documents/overview/renvela-epar-medicine-overview_hu.pdf)

Malti (MT) (105.96 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/mt/documents/overview/renvela-epar-medicine-overview_mt.pdf)

Nederlands (NL) (82.39 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/nl/documents/overview/renvela-epar-medicine-overview_nl.pdf)

polski (PL) (112.71 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/pl/documents/overview/renvela-epar-medicine-overview_pl.pdf)

português (PT) (83.68 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/pt/documents/overview/renvela-epar-medicine-overview_pt.pdf)

română (RO) (103.76 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/ro/documents/overview/renvela-epar-medicine-overview_ro.pdf)

slovenčina (SK) (103.4 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/sk/documents/overview/renvela-epar-medicine-overview_sk.pdf)

slovenščina (SL) (98.64 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/sl/documents/overview/renvela-epar-medicine-overview_sl.pdf)

Suomi (FI) (81.73 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/fi/documents/overview/renvela-epar-medicine-overview_fi.pdf)

svenska (SV) (82.05 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/sv/documents/overview/renvela-epar-medicine-overview_sv.pdf)

Renvela : EPAR - Risk management plan

English (EN) (950.17 KB - PDF)

**First published:** 10/01/2024

[View](/en/documents/rmp/renvela-epar-risk-management-plan_en.pdf)

## Product information

Renvela : EPAR - Product Information

English (EN) (567.45 KB - PDF)

**First published:** 13/08/2009

**Last updated:** 08/01/2025

[View](/en/documents/product-information/renvela-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-410)

български (BG) (764.22 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/bg/documents/product-information/renvela-epar-product-information_bg.pdf)

español (ES) (655.85 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/es/documents/product-information/renvela-epar-product-information_es.pdf)

čeština (CS) (714.6 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/cs/documents/product-information/renvela-epar-product-information_cs.pdf)

dansk (DA) (598.09 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/da/documents/product-information/renvela-epar-product-information_da.pdf)

Deutsch (DE) (606.74 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/de/documents/product-information/renvela-epar-product-information_de.pdf)

eesti keel (ET) (577.56 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/et/documents/product-information/renvela-epar-product-information_et.pdf)

ελληνικά (EL) (752.63 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/el/documents/product-information/renvela-epar-product-information_el.pdf)

français (FR) (744.66 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/fr/documents/product-information/renvela-epar-product-information_fr.pdf)

hrvatski (HR) (725.9 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/hr/documents/product-information/renvela-epar-product-information_hr.pdf)

íslenska (IS) (541.5 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/is/documents/product-information/renvela-epar-product-information_is.pdf)

italiano (IT) (659.33 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/it/documents/product-information/renvela-epar-product-information_it.pdf)

latviešu valoda (LV) (656.74 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/lv/documents/product-information/renvela-epar-product-information_lv.pdf)

lietuvių kalba (LT) (688.54 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/lt/documents/product-information/renvela-epar-product-information_lt.pdf)

magyar (HU) (696.86 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/hu/documents/product-information/renvela-epar-product-information_hu.pdf)

Malti (MT) (773.96 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/mt/documents/product-information/renvela-epar-product-information_mt.pdf)

Nederlands (NL) (563.77 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/nl/documents/product-information/renvela-epar-product-information_nl.pdf)

norsk (NO) (605.6 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/no/documents/product-information/renvela-epar-product-information_no.pdf)

polski (PL) (719.25 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/pl/documents/product-information/renvela-epar-product-information_pl.pdf)

português (PT) (581.35 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/pt/documents/product-information/renvela-epar-product-information_pt.pdf)

română (RO) (740.83 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/ro/documents/product-information/renvela-epar-product-information_ro.pdf)

slovenčina (SK) (706.23 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/sk/documents/product-information/renvela-epar-product-information_sk.pdf)

slovenščina (SL) (673.52 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/sl/documents/product-information/renvela-epar-product-information_sl.pdf)

Suomi (FI) (543.1 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/fi/documents/product-information/renvela-epar-product-information_fi.pdf)

svenska (SV) (560.77 KB - PDF)

**First published:**

13/08/2009

**Last updated:**

08/01/2025

[View](/sv/documents/product-information/renvela-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0066 19/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Renvela : EPAR - All Authorised presentations

English (EN) (33.54 KB - PDF)

**First published:** 23/06/2009

**Last updated:** 19/07/2019

[View](/en/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-421)

български (BG) (69.66 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/bg/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.22 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/es/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_es.pdf)

čeština (CS) (98.68 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/cs/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (23.63 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/da/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.21 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/de/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (37.45 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/et/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.08 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/el/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_el.pdf)

français (FR) (49.24 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/fr/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (48.21 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/hr/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (29.05 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/is/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_is.pdf)

italiano (IT) (26.1 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/it/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (44.81 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/lv/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (51.63 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/lt/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (70.77 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/hu/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (44.14 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/mt/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (25.69 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/nl/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (33.61 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/no/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_no.pdf)

polski (PL) (47.28 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/pl/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.22 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/pt/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_pt.pdf)

română (RO) (46.11 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/ro/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (51.49 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/sk/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (43.25 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/sl/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.33 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/fi/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (32.02 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

19/07/2019

[View](/sv/documents/all-authorised-presentations/renvela-epar-all-authorised-presentations_sv.pdf)

Renvela : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (15.8 KB - PDF)

**First published:** 23/06/2009

**Last updated:** 23/06/2009

[View](/en/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (21)](#file-language-dropdown-378)

български (BG) (75.18 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/bg/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (16.27 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/es/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (79.92 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/cs/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (16.36 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/da/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (16.76 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/de/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (16.24 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/et/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (71.18 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/el/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (16.91 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/fr/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

italiano (IT) (16.78 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/it/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (80.68 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/lv/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (82.72 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/lt/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (51.05 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/hu/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (83.26 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/mt/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (16.79 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/nl/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

polski (PL) (79.57 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/pl/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (16.55 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/pt/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (96.77 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/ro/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (80.09 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/sk/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (74.32 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/sl/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (16.25 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/fi/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (16.41 KB - PDF)

**First published:**

23/06/2009

**Last updated:**

23/06/2009

[View](/sv/documents/conditions-member-states/renvela-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Renvela Active substance sevelamer carbonate International non-proprietary name (INN) or common name sevelamer carbonate Therapeutic area (MeSH)

- Hyperphosphatemia
- Renal Dialysis

Anatomical therapeutic chemical (ATC) code V03AE02

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.

Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.

Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D 3 or one of its analogues to control the development of renal bone disease.

## Authorisation details

EMA product number EMEA/H/C/000993 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail 94250 Gentilly France

Opinion adopted 19/03/2009 Marketing authorisation issued 09/06/2009 Revision 29

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Renvela : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (249.24 KB - PDF)

**First published:** 13/08/2009

**Last updated:** 08/01/2025

[View](/en/documents/procedural-steps-after/renvela-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Renvela-H-C-PSUSA-00002697-201810 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/462037/2019

English (EN) (68.1 KB - PDF)

**First published:** 03/09/2019

[View](/en/documents/scientific-conclusion/renvela-h-c-psusa-00002697-201810-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Renvela-H- C-993-WS-0965 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/352101/2017

English (EN) (802.77 KB - PDF)

**First published:** 26/07/2017

**Last updated:** 26/07/2017

[View](/en/documents/variation-report/renvela-h-c-993-ws-0965-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Renvela (WS/965)

Adopted

Reference Number: EMA/CHMP/314225/2017

English (EN) (68.56 KB - PDF)

**First published:** 22/05/2017

**Last updated:** 22/05/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-renvela-ws965_en.pdf)

Renvela-H-C-PSUSA-00002697-201510 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/571186/2016

English (EN) (74.04 KB - PDF)

**First published:** 30/08/2016

**Last updated:** 30/08/2016

[View](/en/documents/scientific-conclusion/renvela-h-c-psusa-00002697-201510-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Renvela-H-C-993-P46-0023 : EPAR - Assessment Report

Adopted

Reference Number: EMA/271022/2016

English (EN) (223.94 KB - PDF)

**First published:** 11/05/2016

**Last updated:** 11/05/2016

[View](/en/documents/variation-report/renvela-h-c-993-p46-0023-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Renvela : EPAR - Public assessment report

English (EN) (659.67 KB - PDF)

**First published:** 23/06/2009

**Last updated:** 23/06/2009

[View](/en/documents/assessment-report/renvela-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Renvela

Reference Number: EMEA/CHMP/175954/2009

English (EN) (34.33 KB - PDF)

**First published:** 19/03/2009

**Last updated:** 19/03/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-renvela_en.pdf)

#### News on Renvela

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/01/2025

## Share this page

[Back to top](#main-content)